Literature DB >> 9732217

Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.

C Nicolaides1, G Fountzilas, N Zoumbos, D Skarlos, P Kosmidis, D Pectasides, A Karabelis, T Giannakakis, A Symeonidis, A Papadopoulos, F Antoniou, N Pavlidis.   

Abstract

Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently formulated. We tried to identify the clinical prognostic factors that predict treatment outcome in Greek patients with diffuse large cell lymphomas and validated the IPI in these patients. The possible prognostic variables for tumor response, relapse-free (RFS) and overall survival (OS) were analyzed in 239 consecutive patients treated with anthracycline-based chemotherapy regimens. In univariate analysis, factors associated with poor response were stages III-IV, performance status (PS) >/=2, spleen and bone marrow involvement, more than one extranodal site involved, increased lactate dehydrogenase (LDH) value, hemoglobin (Hb) <12 g/dl, albumin <3.5 g/dl, erythrocyte sedimentation rate (ESR) >50 mm/h. Multivariate analysis identified stage, PS, more than one extranodal site involved, increased LDH level, and ESR > 50 mm/h as the factors more predictive of poor response. For RFS, multiple Cox analysis found stages III-IV and bone marrow involvement to be statistically significant. For OS, multiple Cox analysis identified stage III-IV, PS >/=2, bone marrow involvement, more than one extranodal site involved, increased LDH level and ESR > 50 mm/h as negative prognostic factors. Patients stratified in the different risk groups of the IPI had a significantly different outcome regarding complete response (CR) rate, RFS and OS. In conclusion, although age >60 years was not recognized as an adverse factor in this analysis, our patients stratified in the different groups of the IPI had significant differences in CR rate, 2-year RFS and OS verifying the prognostic significance of the index. Bone marrow involvement and ESR > 50 mm/h, parameters that are not included in the IPI, adversely affected survival.

Entities:  

Mesh:

Year:  1998        PMID: 9732217     DOI: 10.1159/000011886

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma.

Authors:  Basem Magdy William; Navneeth Rao Bongu; Martin Bast; Robert Gregory Bociek; Philip Jay Bierman; Julie Marie Vose; James Olen Armitage
Journal:  Rev Bras Hematol Hemoter       Date:  2013

2.  Prognostic significance of biochemical markers in African Burkitt's lymphoma.

Authors:  F K N Arthur; L Owusu; F A Yeboah; T Rettig; A Osei-Akoto
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

3.  Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling.

Authors:  Byong Chul Yoo; Sun-Young Kong; Sang-Geun Jang; Kyung-Hee Kim; Sun-A Ahn; Weon-Seo Park; Sohee Park; Tak Yun; Hyeon-Seok Eom
Journal:  BMC Cancer       Date:  2010-02-23       Impact factor: 4.430

4.  Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.

Authors:  Ting-Xun Lu; Jin-Hua Liang; Yi Miao; Lei Fan; Li Wang; Xiao-Yan Qu; Lei Cao; Qi-Xing Gong; Zhen Wang; Zhi-Hong Zhang; Wei Xu; Jian-Yong Li
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

5.  Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma.

Authors:  Guo Li; Jin Gao; Ya-Lan Tao; Bing-Qing Xu; Zi-Wei Tu; Zhi-Gang Liu; Mu-Sheng Zeng; Yun-Fei Xia
Journal:  Chin J Cancer       Date:  2012-01-09

6.  Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment.

Authors:  Yun-Ming Tian; Lei Zeng; Feng-Hua Wang; Shuai Liu; Ying Guan; Tai-Xiang Lu; Fei Han
Journal:  Radiat Oncol       Date:  2013-11-19       Impact factor: 3.481

7.  Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts.

Authors:  Vivek Kumar; Parita Soni; Vishangi Dave; Jonathan Harris
Journal:  J Investig Med High Impact Case Rep       Date:  2017-02-01

8.  The expression level of hsa-miR-146a-5p in plasma-derived exosomes of patients with diffuse large B-cell lymphoma.

Authors:  Nasrin Zare; Nahid Eskandari; Valiollah Mehrzad; Shaghayegh Haghjooy Javanmard
Journal:  J Res Med Sci       Date:  2019-02-25       Impact factor: 1.852

9.  The clinicopathologic features and response to treatment of patients with Nonhodgkin Lymphoma: A single-center experiment in Turkey.

Authors:  Rahsan Yildirim; Gulden Sincan
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.